Preservation and Expansion of T-Cell Subsets Following HAART De-Intensification to Atazanavir/Ritonavir (ATV/r) in Adolescents With CD4 + T Cells greater than 350 Cells/mm3 Initiating HAART.

Trial Profile

Preservation and Expansion of T-Cell Subsets Following HAART De-Intensification to Atazanavir/Ritonavir (ATV/r) in Adolescents With CD4 + T Cells greater than 350 Cells/mm3 Initiating HAART.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Atazanavir/ritonavir (Primary) ; Atazanavir; Emtricitabine; Lamivudine; Ritonavir; Tenofovir disoproxil fumarate; Zidovudine
  • Indications HIV-1 infections
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2012 Planned end date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top